Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 5/2021

01-10-2021 | Prostate Cancer | Original Article

Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617

Authors: Elahe Mahmoudi, Elahe Pirayesh, Mohammad Reza Deevband, Mahasti Amoui, Mehrdad Ghorbani Rad, Mahdi Ghorbani

Published in: Nuclear Medicine and Molecular Imaging | Issue 5/2021

Login to get access

Abstract

Purpose

177Lu-DKFZ-PSMA-617 is a promising treatment for patients with metastatic prostate cancer. Specific dosimetry for each patient is an important factor in planning the patient’s treatment process. This study aimed to perform an image-based absorbed dose calculation for the treatment of metastatic prostate cancer with 177Lu-DKFZ-PSMA-617.

Methods

The individualized patient dosimetry calculations were based on whole-body planar scintigraphy images acquired in 10 patients with a mean age of 71.4 ± 6.07 years (range 63–85 years) at approximately 0–2 h, 4–6 h, 18–24 h, and 36–48 h after administration of the mean 6253 ± 826.4 MBq (range 5500–7400 MBq) of 177Lu-DKFZ-PSMA-617. Time-activity curves were generated for various organs. For count conversion to activities, calibration factors were calculated. Finally, the absorbed dose for an individual cycle was calculated using IDIAC-DOSE 2.1 software.

Results

On average, the calculated absorbed dose for the kidneys and salivary glands were 0.46 ± 0.09 mGy/MBq and 0.62 ± 0.07 mGy/MBq, respectively.

Conclusions

Based on the results, the177Lu-PSMA-617 therapy is a safe method for the treatment of castration-resistant prostate cancer patients. Large inter-individual variations in organ dose were found, demonstrating the need for patient-specific dosimetry and treatment planning.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRef
2.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRef
3.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92.CrossRef
4.
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.CrossRef
5.
Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92.CrossRef
6.
Eiber M, Nekolla SG, Maurer T, Weirich G, Wester HJ, Schwaiger M. (68) Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging. 2015;40:1769–71.CrossRef
7.
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28.CrossRef
8.
Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benes ova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705.CrossRef
9.
Ristau BT, O’Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2014;32:272–9.CrossRef
10.
Klein Nulent TJ, Valstar MH, de Keizer B, Willems SM, Smit LA, Al-Mamgani A, et al. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:478–86.CrossRef
11.
Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, Kopka K, et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987–8.CrossRef
12.
Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42–51.CrossRef
13.
Sarnelli A, Belli ML, Di Iorio V, Mezzenga E, Celli M, Severi S, Tardelli E, Nicolini S, Oboldi D, Uccelli L, Cittanti C, Monti M, Ferrari M, Paganelli G. Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: preliminary results of EUDRACT/RSO 2016–002732-32 IRST protocol. Molecules. 2019;11(24):621.CrossRef
14.
Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, Drzezga A, Wild M. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with 177 Lu DKFZ-PSMA-617. Mol Imaging Biol. 2016;18:437–45.CrossRef
15.
Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976–83.CrossRef
16.
Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, Aygün A, Karayel E, Pehlivanoğlu H, Alan SN. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther. 2017;26:62–8.CrossRef
17.
Divoli A, Chiavassa S, Ferrer L, Barbet J, Flux GD, Bardiès M. Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies. J Nucl Med. 2009;50:316–23.CrossRef
18.
Howard DM, Kearfott KJ, Wilderman SJ, Dewaraja YK. Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations. Cancer Biother Radiopharm. 2011;26:615–21.CrossRef
19.
Senthamizhchelvan S, Hobbs RF, Song H, et al. Tumor dosimetry and response for 153Sm-ethylenediamine tetra methylene phosphoric acid therapy of high-risk osteosarcoma. J Nucl Med. 2012;53:215–24.CrossRef
20.
Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7:88.CrossRef
21.
Miller C, Filipow L, Jackson S. A review of activity quantification by planar imaging methods. J Nucl Med Technol. 1995;23:3–9.
22.
Stabin MG. Fundamentals of nuclear medicine dosimetry. 1st ed. New York: Springer Verlag; 2008.
23.
Konijnenberg MW, Bijster M, Krenning EP, De Jong M. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90) Y, (111) In, or (177) Lu. J Nucl Med. 2004;45:1260–9 ([published correction appears in J Nucl Med 2009 Dec 50(12):2092).PubMed
24.
Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310.CrossRef
25.
ICRP89. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2002;32:5–265.CrossRef
26.
Snyder WS, Fisher Jr HL, Ford MR, Warner GG. MIRD pamphlet no. 5, revised: Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. J Nucl Med. 1969;Suppl 3:7–52.
Metadata
Title
Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617
Authors
Elahe Mahmoudi
Elahe Pirayesh
Mohammad Reza Deevband
Mahasti Amoui
Mehrdad Ghorbani Rad
Mahdi Ghorbani
Publication date
01-10-2021
Publisher
Springer Singapore
Published in
Nuclear Medicine and Molecular Imaging / Issue 5/2021
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-021-00713-7

Other articles of this Issue 5/2021

Nuclear Medicine and Molecular Imaging 5/2021 Go to the issue

Review

KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future

Case Report

Radioguided Surgery in Insulinoma Using 68Ga Labeled Exendin-4: a Case Report

Original Article

Simulating dose reduction for myocardial perfusion SPECT using a Poisson resampling method

Case Report

68Ga-FAPI-46 PET/MR Detects Recurrent Cholangiocarcinoma and Intraductal Papillary Mucinous Neoplasm in a Patient Showing Increasing CEA with Negative 18F-FDG PET/CT and Conventional CT

Review

KSNM60 in Clinical Nuclear Oncology

Review

Imaging in Tumor Immunology